Ascletis Pharma Inc./歌礼生物科技（杭州)有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody 2020-01-23 09:52
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout 2019-11-29 08:00
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer 2019-10-08 08:00
Ascletis Announces Departure of Chief Financial Officer 2019-09-30 16:30
Ascletis Announces Departure of Chief Financial Officer 2019-09-30 16:30
Ascletis Received IND Approval for its NASH Drug 2019-08-28 08:00
Ascletis Opens Clinical Development Shanghai Center 2019-08-12 18:00
Ascletis Received IND Approval and Management Outlook of 2019 and Beyond 2019-08-05 08:00
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH 2019-05-01 06:00
Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease 2019-04-15 17:12
Ascletis Appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China 2019-03-01 08:00
Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing 2019-02-13 08:00
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases 2019-01-14 08:30
Ascletis' IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA 2019-01-03 08:00
Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu 2019-01-02 08:00
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis 2018-11-20 18:30
Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer 2018-11-12 07:30
Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD 2018-11-06 08:00
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA 2018-10-18 16:30
Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients 2018-10-15 16:30
1 5 6 7 8 9